| 2026-04-22 | Mr. Jason VanWeesVice Chair | -65,00 | 0,00 | Derivative Exercise and Sale | - | 53,73k | - |
| 2026-04-22 | Mr. Jason VanWeesVice Chair | 61,00 | 0,00 | Derivative Exercise and Retained Stock | - | 53,73k | 0,11% |
| 2026-02-03 | Mr. Jason VanWeesVice Chair | -7,50k | 3,46M | Derivative Exercise and Sale | 123,38 - 631,39 | 53,67k | - |
| 2026-01-28 | Mr. Michael T. SmithLead Independent Director | -4,00k | 2,48M | Verkauf | 621,00 | 46,86k | -7,86% |
| 2026-01-23 | Mr. Jason VanWeesVice Chair | 71,00 | 0,00 | Derivative Exercise and Retained Stock | - | 53,67k | 0,13% |
| 2026-01-23 | Mr. Jason VanWeesVice Chair | -50,00 | 0,00 | Derivative Exercise and Sale | - | 53,67k | - |
| 2026-01-24 | Mr. Jason VanWeesVice Chair | -344,00 | 0,00 | Sale to Issuer | - | 53,67k | -0,64% |
| 2026-01-24 | Ms. Melanie Susan CibikExec. VP, General Counsel, Secretary & CCO | -310,00 | 0,00 | Sale to Issuer | - | 26,25k | -1,17% |
| 2026-01-24 | Mr. George C. BobbPresident, CEO & Director | -440,00 | 0,00 | Sale to Issuer | - | 9,96k | -4,23% |
| 2026-01-24 | Mr. Stephen Finis BlackwoodCFO & Exec. VP | -260,00 | 0,00 | Sale to Issuer | - | 11,42k | -2,23% |
| 2026-01-24 | Ms. Cynthia Y. BelakSenior VP & Controller | -249,00 | 0,00 | Sale to Issuer | - | 4,64k | -5,09% |
| 2026-01-24 | Dr. Robert MehrabianExecutive Chairman | -2,98k | 0,00 | Sale to Issuer | - | 127,17k | -2,29% |
| 2025-09-12 | Ms. Jane C. SherburneIndependent Director | -2,00k | 1,11M | Verkauf | 554,76 | 2,42k | -45,27% |
| 2025-07-30 | Mr. George C. BobbPresident, CEO & Director | -6,74k | 2,28M | Derivative Exercise and Sale | 217,39 - 556,21 | 10,39k | - |
| 2025-07-28 | Mr. Michael T. SmithLead Independent Director | -1,98k | 1,11M | Verkauf | 560,10 | 50,86k | -3,74% |
| 2025-07-28 | Dr. Robert MehrabianExecutive Chairman | -14,40k | 0,00 | Other Disposition | - | 130,15k | -9,96% |
| 2025-07-25 | Mr. Simon Michael LorneIndependent Director | -6,31k | 3,47M | Verkauf | 549,27 - 551,29 | 58,53k | -9,73% |